Literature DB >> 19420766

Efficient short interference RNA delivery to tumor cells using a combination of octaarginine, GALA and tumor-specific, cleavable polyethylene glycol system.

Yu Sakurai1, Hiroto Hatakeyama, Hidetaka Akita, Motoi Oishi, Yukio Nagasaki, Shiro Futaki, Hideyoshi Harashima.   

Abstract

We recently developed a multifunctional envelope-type nano device (MEND) for efficient nucleic acid delivery. Here, we report on the development of an octaarigine (R8)-modified MEND encapsulating small interfering RNA (siRNA) with a tumor-specific, cleavable, polyethylene glycol (PEG)-lipid (PPD). We first determined the optimal concentration of R8 and pH-sensitive fusogenic peptide (GALA) on the lipid envelope of MEND (R8/GALA-MEND). Then, we examined the combination of optimized R8/GALA-MEND with a PEG-lipid. When a conventional PEG-lipid was used, the R8/GALA-MEND failed to knockdown expression of the target gene. On the other hand, PPD-modified R8/GALA-MEND exhibited efficient silencing activity to the level of the PEG-unmodified R8/GALA-MEND. In addition, we compared a R8/GALA-MEND with a MEND composed of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) that is a conventional cationic lipid used as a lipoplex component. The knockdown ability of the R8/GALA-MEND was much higher than that of the DOTAP-based MEND at the dose that is commonly employed in in vitro siRNA transfection. These results demonstrate that the R8/GALA-MEND is a promising delivery system for the transfer of siRNA to tumor cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19420766     DOI: 10.1248/bpb.32.928

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  10 in total

Review 1.  Subcellular fate and off-target effects of siRNA, shRNA, and miRNA.

Authors:  Saurabh Singh; Ajit S Narang; Ram I Mahato
Journal:  Pharm Res       Date:  2011-10-28       Impact factor: 4.200

Review 2.  Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor.

Authors:  Yinghuan Li; Jie Wang; M Guillaume Wientjes; Jessie L-S Au
Journal:  Adv Drug Deliv Rev       Date:  2011-05-03       Impact factor: 15.470

Review 3.  Functional peptides for siRNA delivery.

Authors:  Wanyi Tai; Xiaohu Gao
Journal:  Adv Drug Deliv Rev       Date:  2016-08-13       Impact factor: 15.470

Review 4.  Principles in the design of ligand-targeted cancer therapeutics and imaging agents.

Authors:  Madduri Srinivasarao; Chris V Galliford; Philip S Low
Journal:  Nat Rev Drug Discov       Date:  2015-02-20       Impact factor: 84.694

5.  A DNA microarray-based analysis of the host response to a nonviral gene carrier: a strategy for improving the immune response.

Authors:  Hiroto Hatakeyama; Erika Ito; Momoko Yamamoto; Hidetaka Akita; Yasuhiro Hayashi; Kazuaki Kajimoto; Noritada Kaji; Yoshinobu Baba; Hideyoshi Harashima
Journal:  Mol Ther       Date:  2011-03-08       Impact factor: 11.454

Review 6.  New Technologies Bloom Together for Bettering Cancer Drug Conjugates.

Authors:  Yiming Jin; Shahab Edalatian Zakeri; Raman Bahal; Andrew J Wiemer
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

Review 7.  Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy.

Authors:  Srinivas Ramishetti; Leaf Huang
Journal:  Ther Deliv       Date:  2012-12

8.  Optimization of Non-Viral Gene Therapeutics Using Bilamellar Invaginated Vesicles.

Authors:  Nancy Smyth Templeton; Neil Senzer
Journal:  J Genet Syndr Gene Ther       Date:  2011-12-17

9.  Reversible masking using low-molecular-weight neutral lipids to achieve optimal-targeted delivery.

Authors:  Nancy Smyth Templeton; Neil Senzer
Journal:  J Drug Deliv       Date:  2012-05-10

10.  Application of apolipoprotein E-modified liposomal nanoparticles as a carrier for delivering DNA and nucleic acid in the brain.

Authors:  Mina Tamaru; Hidetaka Akita; Taichi Nakatani; Kazuaki Kajimoto; Yusuke Sato; Hiroto Hatakeyama; Hideyoshi Harashima
Journal:  Int J Nanomedicine       Date:  2014-09-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.